CUA Educational Content

PSMA PET/CT Beyond the Images: The Imager’s and Clinician’s Perspective

EDITORIAL COMMITTEE: Bobby Shayegan, Katherine Zukotynski, Frédéric Pouliot, Stefano Fanti


By the end of this program, participants will be able to:

  • Describe the several PSMA-targeting tracers and PET/CT technology
  • Describe the accuracy of PSMA-PET/CT for staging and re-staging prostate cancer based on best prospective studies
  • Understand the basis of PSMA radioligand therapy and the trials in metastatic prostate cancer
 
Start Quiz for Credits

 

 

This program has received financial support from The ICPO Foundation, Oncidium Foundation, and Advanced Accelerator Applications: A Novartis Company in the form of an educational grant

The Canadian Urological Association (CUA) does not provide professional medical advice, diagnosis or treatment and cannot respond to requests for direct feedback, specific patient information or physician referrals. You should first always seek the advice of your urologist, physician and other qualified health provider with any questions regarding your medical condition. The contents of the CUA Website such as text, graphics, images, and other content are for informational purposes only. The content/information is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on the CUA website.

For comments or information, email Corporate.office@cua.org

Privacy Policy